ENGN Stock Analysis

enGene Holdings Inc. Common Stock
HEALTHCARE BIOTECHNOLOGY

Back to Winners View Yahoo Finance Chart Buy on the Dip
Strong Caution Mixed Weak Unavailable
StockValueFinder Grade
F
25.52 / 100
Weak
Confidence: Moderate (74.0%) Coverage: 74.0%
Business Quality 11.1
Financial Strength 43.0
Earnings & Growth 35.7
Valuation 27.5
Market Strength 10.0
The grade combines Business Quality, Financial Strength, Earnings & Growth, Valuation, and Market Strength. Rating and Trend remain separate signals.
Rating AVOID
Avoid
The screening rules are warning against this setup.
Rating is the simple decision label from the screening rules.
Trend SELL / AVOID TREND
Weak Trend
The current trend is unfavorable.
Trend shows whether price action is helping or hurting the setup.
P/E Ratio -0.69
Not Meaningful
Negative or missing earnings make P/E hard to use.
P/E shows how much investors pay for each dollar of earnings.
ROIC -58.80%
Poor
Negative ROIC suggests capital is not being used profitably.
ROIC measures how efficiently capital turns into profit.
Debt Payback -0.15 yrs
Unavailable
Debt payback is unavailable or not meaningful.
Debt payback estimates how quickly debt could be covered.
Interest Coverage -41.14x
Poor
Negative coverage means earnings are not covering interest costs.
Interest coverage shows how easily earnings cover interest costs.
Price $1.58
Market Price
Price alone is not a buy or sell signal.
Price should be judged with valuation, quality, and trend.
Last updated: 2026-10-23 12:16:33

Performance Overview

Trailing adjusted-close returns as of 2026-07-06. Benchmark is SPY.

YTD Return

ENGN -78.85%
SPY +10.76%

1-Year Return

ENGN -49.74%
SPY +21.47%

3-Year Return

ENGN N/A
SPY +77.37%

5-Year Return

ENGN N/A
SPY +85.71%

Returns are calculated from adjusted close prices and may differ from broker or research-site totals depending on data source, dividend handling, benchmark choice, and latest available trading date.

Legacy Screening Checks

This page uses cached SQL data from the latest StockValueFinder scan, so it loads fast without hitting Alpha Vantage on every page view.

33%
EPS Strength
FAIL

Looks for positive and improving earnings per share.

ROIC 10%+
FAIL

Looks for strong return on invested capital.

Interest Coverage 6+
FAIL

Checks whether operating income comfortably covers interest expense.

Debt Payback ≤ 3 Years
PASS

Checks whether free cash flow could pay down long-term debt quickly.

P/E 15 or Less
PASS

Checks whether valuation is reasonable under the current rule set.

Moving Average Trend
SELL / AVOID TREND

Uses 20-day, 50-day, and 200-day moving averages for entry timing context.

A high StockValueFinder score is a research signal, not a guarantee. Strong companies can still fall during recessions, sector downturns, valuation resets, or company-specific events. Always review the business, risks, SEC filings, valuation, and your personal investment goals before buying.

Cached Technical Data

Moving average values from the latest stored scan.

20-Day MA1.77
50-Day MA1.82
200-Day MA4.58
MA Score0

Latest Published Stock Research

Research generated: October 23, 2026

ENGN Stock Analysis: Why enGene Holdings Inc. Common Stock Scored 33% in Stock Value Finder

Analyzing enGene Holdings Inc. (ENGN): An Educational StockValueFinder Research Report

This article provides a detailed educational review of enGene Holdings Inc. Common Stock (ENGN), a company operating within the Healthcare sector and specifically the Biotechnology industry. This report is an automated research summary generated by StockValueFinder.com to help investors understand how specific financial metrics are used to evaluate the quality, valuation, and risk profile of a security.

The purpose of this research is not to provide a recommendation, but to demonstrate the mechanics of fundamental analysis. By examining the data points provided for enGene Holdings Inc., readers can learn how to apply these same quantitative standards to other companies in the biotechnology sector.

Overview of enGene Holdings Inc. (ENGN)

enGene Holdings Inc. is categorized within the Biotechnology industry. In this sector, companies often face high levels of research and development costs, significant capital requirements, and intense competition. Because biotechnology firms frequently operate in a high-risk environment involving regulatory hurdles and long development cycles, disciplined financial scrutiny is essential.

At the time of this report, the recent price for ENGN is $1.58. As we move through the data, we will see how this price interacts with various valuation and efficiency metrics to form a complete picture of the company's current financial standing.

Why the StockValueFinder Score Matters

The StockValueFinder score for enGene Holdings Inc. is 33%. This score is a composite metric derived from multiple fundamental tests, including profitability, debt management, and valuation.

In the StockValueFinder methodology, a higher score generally indicates that a company is meeting more of the criteria for financial health and valuation discipline. A score of 33% results in a rating of **AVOID**. This rating is not a prediction of future price movement, but rather a reflection that the company has failed several key quantitative benchmarks required to pass our screening process. When a stock receives an "Avoid" rating, it means the mathematical evidence suggests the company currently lacks the stability or value characteristics typically sought by disciplined investors.

EPS Strength and Consistency

Earnings Per Share (EPS) is a critical metric for assessing the profitability of a company on a per-share basis. Consistency in EPS is vital because it demonstrates a company's ability to generate actual profit for its shareholders over time, rather than relying on one-time gains or capital infusions.

For enGene Holdings Inc., the system recorded that the company **did not pass** the EPS test. While the specific historical EPS values were not supplied in this data set, a "fail" result indicates that the company's earnings history does not meet the required thresholds for stability and positive growth.

**Educational Example:** When evaluating other stocks, look for a history of steady or growing EPS. For instance, if Company A has an EPS that grows from $1.00 to $1.20 over three years, it shows earnings strength. If Company B has an EPS that fluctuates wildly between -$2.00 and +$0.50, it demonstrates high earnings volatility, which is a risk factor for investors seeking predictability.

ROIC and Capital Efficiency

Return on Invested Capital (ROIC) is a measure of how effectively a company uses the money it has raised (through debt and equity) to generate profits. It is one of the most important metrics for determining if a business is creating value or destroying it.

The supplied ROIC for enGene Holdings Inc. is **-58.80%**.

In professional financial analysis, a strong or attractive ROIC is generally considered to be 10% or higher. A positive ROIC indicates that the company is generating more cash than it costs to maintain its operations and capital base. A negative ROIC, such as the -58.80% seen here, indicates that for every dollar of capital invested in the business, the company is losing value.

**Educational Example:** Consider two companies: Company X has an ROIC of 15%, while Company Y has an ROIC of 4%. Company X is using its capital much more efficiently to generate returns. In the case of ENGN, a negative ROIC suggests that capital is being consumed rather than multiplied, which represents a significant risk to long-term capital preservation.

Interest Coverage and Financial Safety

Interest coverage is a solvency ratio that measures how easily a company can pay the interest expenses on its outstanding debt. This is a vital metric for assessing "financial safety," particularly in environments where interest rates may be volatile or rising.

The system recorded that enGene Holdings Inc. **did not pass** the interest coverage test.

StockValueFinder prefers an interest coverage ratio of 6 or higher. A high ratio provides a "buffer," meaning the company can experience a temporary drop in earnings and still meet its debt obligations. A low ratio indicates that even a small dip in cash flow could make it difficult for the company to service its debt.

**Educational Example:** If a company has an interest coverage of 8x, it means its earnings are eight times larger than its interest payments—this is considered healthy. If a company has an interest coverage of 2x, it only has twice as much earnings as it needs to pay its interest. This is a much riskier position, as any economic downturn could leave the company unable to pay its creditors.

Debt Payback and Balance Sheet Discipline

Debt payback refers to the estimated time it would take for a company to pay off its total debt using its current cash flows. This metric helps investors understand the duration of a company's leverage risk.

The supplied debt payback value for enGene Holdings Inc. is **-0.15 years**.

StockValueFinder prefers a debt payback period of 3 years or less. A shorter payback period is generally more attractive because it suggests the company can quickly deleverage and reduce its exposure to creditors. While a negative number in debt payback often indicates complex accounting or specific cash flow structures, the system has marked this test as **Passed**.

**Educational Example:** A company with a debt payback of 1.5 years is in a very strong position to clear its obligations quickly. A company with a debt payback of 7 years is much more vulnerable to long-term economic shifts and changes in the cost of borrowing.

P/E Ratio and Valuation Discipline

The Price-to-Earnings (P/E) ratio is a valuation metric that compares the current share price to the company's earnings per share. It helps investors determine if a stock is "expensive" or "cheap" relative to its profits.

The supplied P/E ratio for enGene Holdings Inc. is **-0.69**.

Because the P/E ratio is negative, it reflects the fact that the company is currently reporting a loss. StockValueFinder typically looks for a P/E of 15 or lower to identify companies with valuation discipline. When a company has negative earnings, the standard P/E ratio becomes less useful for traditional valuation, which is why the system treats this as a "Pass" in terms of the mathematical test (as it cannot be evaluated against a positive target), but the underlying negative earnings remain a fundamental concern.

**Educational Example:** If Company A has a P/E of 8, it means investors are paying $8 for every $1 of earnings. If Company B has a P/E of 40, investors are paying $40 for every $1 of earnings. Generally, a lower P/E can represent better value, provided the company's growth and quality are sustainable.

Moving Average Trend and Entry Timing

Moving averages are used to identify the direction of a stock's price trend over a specific period. This is a tool for "timing discipline," helping investors avoid catching a "falling knife" (buying a stock that is in a continuous downward spiral).

The moving average signal for ENGN is **SELL / AVOID TREND**. Additionally, the entry signal is listed as **N/A**.

It is important to understand that a "Sell/Avoid Trend" does not mean the stock *must* go down; rather, it means the current mathematical trend is downward. Using trend signals helps investors avoid entering positions when the momentum is working against them.

**Educational Example:** If a stock's price is consistently staying below its 200-day moving average, the trend is considered "down." An investor using trend discipline might wait for the price to cross above that average before considering an entry, rather than buying while the trend is still negative.

Overall Financial Strengths and Weaknesses

Based on the supplied data, we can summarize the profile of enGene Holdings Inc. (ENGN) as follows:

**Strengths:** * The company has passed the debt payback test, suggesting a specific structure in its ability to handle debt obligations relative to its current metrics. * The P/E valuation test was passed (mathematically), though the negative value reflects lack of current profitability.

**Weaknesses:** * **Profitability:** The company failed the EPS test and has a deeply negative ROIC of -58.80%, indicating significant capital inefficiency. * **Solvency:** The company failed the interest coverage test, suggesting potential difficulty in meeting interest obligations. * **Trend:** The moving average signal is a "Sell/Avoid Trend," indicating negative price momentum. * **Valuation:** The score of 33% and "Avoid" rating reflect a combination of negative earnings and poor capital efficiency.

Risks and Limitations

Investors should be aware that biotechnology stocks are subject to unique risks, including currency stability issues in global operations, the impact of government debt and interest rate changes on biotech funding, and general long-term investment uncertainty.

Furthermore, this report provides no "Limit Buy" ideas, "Pullback Zones," or "Risk Stop/Trend Risk Levels" (all marked N/A). This means there are no identified technical entry or exit points provided by the system for this security. Investors should not view the absence of these numbers as a suggestion to wait, but rather as an indication that no specific technical setup has been identified by the current parameters.

Educational Conclusion

In summary, enGene Holdings Inc. (ENGN) presents a profile characterized by negative earnings and negative return on invested capital. While the company has passed certain debt-related tests, its failure to meet EPS, ROIC, and interest coverage benchmarks results in a low StockValueFinder score of 33% and an "Avoid" rating.

For those learning to evaluate stocks, ENGN serves as a case study in why looking at a single number—like price—is insufficient. A low price of $1.58 does not inherently mean a stock is "cheap" if the ROIC is -58.80% and the interest coverage is insufficient to cover debt obligations. True value is found by looking at the intersection of price, profitability, and financial safety.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.


Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings

Research Attribution
Mac Gemton IV

Mac Gemton IV is a financial research analyst specializing in equity valuation, ETF performance, dividend income strategies, and investment risk assessment. With a disciplined, data-driven approach, he examines company fundamentals, earnings growth, balance-sheet strength, valuation ratios, historical returns, and market trends. His research focuses on identifying financial strengths, potential risks, and long-term investment considerations, transforming complex financial data into clear, practical analysis for everyday investors.

30-Day Trendline Analysis

Optional intraday chart with rising support, falling resistance, and multi-timeframe views.

Load detailed price structure only when needed. Downloads roughly 30 days of 5-minute candles, identifies swing points, then calculates validated support and resistance lines.
Scroll to Top